Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

BACKGROUND: ER-positive (ER+ ) breast cancer includes all of the intrinsic molecular subtypes, although the luminal A and B subtypes predominate. In this study, we evaluated the ability of six clinically relevant genomic signatures to predict relapse in patients with ER+ tumors treated with adjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales: Prat, A., Parker, J. S., Fan, C., Cheang, M. C. U., Miller, L. D., Bergh, J., Chia, S. K. L., Bernard, P. S., Nielsen, T. O., Ellis, M. J., Carey, L. A., Perou, C. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477878/
https://www.ncbi.nlm.nih.gov/pubmed/22532584
http://dx.doi.org/10.1093/annonc/mds080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477878/
https://www.ncbi.nlm.nih.gov/pubmed/22532584
http://dx.doi.org/10.1093/annonc/mds080

Ejemplares similares